Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40537 BRIGHT HEALTH GROUP, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4991296 (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40537 BRIGHT HEALTH GROUP, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4991296 (State o ...

Bright Health Group, Inc. (BHG) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ET Company Participants Stephen Hagan - Investor Relations Director Mike Mikan - President and Chief Executive Officer Cathy Smith - Chief Financial Officer and Chief Administrative Officer Conference Call Participants Joshua Raskin - Nephron Research Ben Rossi - Citigroup Kevin Fischbeck - Bank of America Justin Lake - Wolfe Research Nathan Rich - Goldman Sachs Operator Hello, and welcome to the Bright Health Group Fourt ...

业绩总结 - Bright Health Group 2022年第四季度收入为5.514亿美元，同比增长45%[7] - 2022年全年收入为24.12亿美元，同比增长59%[10] - 2022年第四季度调整后EBITDA为-1.085亿美元，较2021年同期改善31.8%[7] - 2022年全年调整后EBITDA为-2.335亿美元，较2021年同期改善21.2%[10] - 截至2022年第四季度，Bright Health Group的净亏损为6.38亿美元[11] 成本与比率 - 2022年第四季度医疗成本比率（MCR）为100.1%，较2021年同期的96.9%有所上升[7] - 2022年全年医疗成本比率（MCR）为93.9%，较2021年同期的97.3%有所改善[10] - 2023年预计医疗成本比率将在86%至88%之间[14] 未来展望 - 预计2023年收入将在29亿至31亿美元之间[14] - 预计2023年调整后EBITDA将实现盈利[14] 非GAAP财务指标 - 公司无法提供调整后的EBITDA和调整后的运营成本比率与最直接可比的GAAP财务指标的调节，因为预测非GAAP调整的发生及其财务影响存在不确定性[36] - 调整后的EBITDA可能包括利息支出、所得税支出、折旧和摊销、商誉或无形资产减值、交易成本、基于股份的补偿费用等项目的影响[36] - 公司历史上已将上述项目排除在非GAAP财务指标之外[36] - 调整后的运营成本比率可能包括基于股份的补偿、或有对价公允价值变动、合同终止成本及折旧和摊销的影响[36] - 公司预计将继续在未来的非GAAP财务指标披露中排除这些项目[36] - 非GAAP调整的发生通常与业务部分退出等决策和事件相关，这些事件的发生时间具有不可预测性[36] - 公司无法评估缺失信息的可能重要性，这可能对未来业绩产生重大影响[36]

Bright Health Group, Inc. (BHG) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Stephen Hagan - Director, IR Mike Mikan - President & CEO Cathy Smith - CFO & CAO Conference Call Participants Nathan Rich - Goldman Sachs Joshua Raskin - Nephron Research Steven Valiquette - Barclays Lisa Gill - J.P. Morgan Chase Michael Hall - Morgan Stanley Kevin Fischbeck - Bank of America Gary Taylor - Cowen Operator Hello and welcome to today's Bright Health Group Third Quarter 2022 Earnin ...

| --- | --- | |-------------------------------------------------------------------|-------| | | | | | | | | | | Bright Health Group Third Quarter 2022 – Earnings Presentation | | | November 9, 2022 | | Disclaimer 2 Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements, and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results o ...

| --- | --- | |-------------------------------------------------------------------|-------| | | | | | | | | | | Bright Health Group Second Quarter 2022 – Earnings Presentation | | | August 10, 2022 | | Disclaimer 2 Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements, and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results o ...

Bright Health Group, Inc. (BHG) Q2 2022 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Stephen Hagan - Director, IR Mike Mikan - President & CEO Cathy Smith - CFO & CAO Conference Call Participants Lisa Gill - J.P. Morgan Steven Valiquette - Barclays Nathan Rich - Goldman Sachs Joshua Raskin - Nephron Research Jeff Garro - Piper Sandler Michael Hall - Morgan Stanley Jason Cassorla - Citi Justin Lake - Wolfe Research Kevin Fischbeck - Bank of America Ben Hendrix - RBC Capital Market ...

Bright Health Group, Inc. (BHG) Q1 2022 Results Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Stephen Hagan - Director, Investor Relations Mike Mikan - Vice Chairman, President and Chief Executive Officer Cathy Smith - Chief Financial Officer and Chief Administrative Officer Conference Call Participants Lindsay Golub - Goldman Sachs Calvin Sternick - J.P. Morgan Joshua Raskin - Nephron Research Jason Cassorla - Citigroup Kevin Fischbeck - Bank of America Merrill Lynch Christine Lung - ...

| --- | --- | |-------------------------------------------------------------------------------|-------| | | | | | | | | | | Bright Health Group First Quarter 2022 – Earnings Presentation May 4, 2022 | | Disclaimer 2 Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements, and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results ...